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Abstract
Exogenous neurotrophin delivery to the deaf cochlea can prevent deafness-induced auditory neuron degeneration,
however, we have previously reported that these survival effects are rapidly lost if the treatment stops. In addition, there are
concerns that current experimental techniques are not safe enough to be used clinically. Therefore, for such treatments to
be clinically transferable, methods of neurotrophin treatment that are safe, biocompatible and can support long-term
auditory neuron survival are necessary. Cell transplantation and gene transfer, combined with encapsulation technologies,
have the potential to address these issues. This study investigated the survival-promoting effects of encapsulated BDNF
over-expressing Schwann cells on auditory neurons in the deaf guinea pig. In comparison to control (empty) capsules, there
was significantly greater auditory neuron survival following the cell-based BDNF treatment. Concurrent use of a cochlear
implant is expected to result in even greater auditory neuron survival, and provide a clinically relevant method to support
auditory neuron survival that may lead to improved speech perception and language outcomes for cochlear implant
patients.
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Introduction
Sensorineural hearing loss (SNHL) accounts for 80–90% of all
cases of hearing loss, and is a form of deafness associated with loss
of the auditory hair cells. Hair cell loss may result from acoustic
trauma, ototoxic drugs, cochlear infection, genetic abnormalities
or simply through aging. The cochlear implant, or bionic ear,i sa
neural prosthesis which acts to provide auditory cues to patients
with a severe-to-profound SNHL by circumventing the damaged
or destroyed hair cells to electrically stimulate the primary
auditory neurons of the cochlea. However, auditory neurons
undergo progressive degeneration in SNHL, and so the rescue of
these neurons from deafness-induced degenerative changes may
provide clinical benefits in terms of enhancing speech and
language outcomes in cochlear implant patients.
Auditory neuron degeneration in deafness occurs, at least partly,
because of a loss of endogenous neurotrophic support normally
provided by the hair cells [1–5] and supporting cells [6] of the
organ of Corti. Consequently, treatment of the deafened auditory
system with neurotrophic factors, via various delivery methods, is
reported to elicit protective effects and prevent, or at least slow,
deafness-induced auditory neuron degeneration [7–22]. In
addition, studies investigating the combined application of
neurotrophic factor treatment and chronic electrical stimulation
from a cochlear implant electrode array report enhanced auditory
neuron survival over either treatment alone [17,23], as well as
functional improvements in terms of reduced electrically-evoked
auditory brainstem response thresholds [17,24–26].
However, the current techniques for experimental delivery of
neurotrophins into the cochlea remain unsuitable for use in
human patients. For example, mini-osmotic pumps have a finite
delivery period, and there is also a risk of infection associated with
the insertion of a cannula-based system into the cochlea [27]. In
addition, the survival effects of neurotrophic factors on auditory
neurons are not maintained beyond the treatment period [8,28],
and studies in other neural systems also suggest that the survival
effects of neurotrophic factors only last as long as the treatment
itself [29,30]. While it has been reported that auditory neurons can
survive for up to two weeks after the cessation of intracochlear
BDNF treatment [31], this time-frame is too short to assess if there
are any lasting survival effects in the deaf cochlea, as would be
required for useful clinical application. Interestingly, ongoing
intracochlear electrical stimulation after a short period of
neurotrophin treatment prolongs the neurotrophin-induced sur-
vival effects beyond the period of neurotrophin treatment [28]. It
is therefore important to develop a clinically viable technique for
neurotrophin delivery into the cochlea that can be used in
conjunction with a cochlear implant, and can lead to long-term or
permanent rescue of auditory neurons from the degenerative
effects of deafness.
Transplanting neurotrophin-secreting cells into the deaf cochlea
is a potential therapeutic option for neurotrophin delivery that
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types, including fibroblasts [32–34], Schwann cells [35–38] and
stem cells [39–41] have been successfully genetically modified to
express neurotrophins. These cells can elicit positive effects in
terms of neuronal survival, regeneration, myelination and recovery
of function in various models of neurodegeneration [32–38,40,41].
Importantly, long-term neurotrophin expression of over 12
months is possible [42].
For clinical application in deafness, cell transplantation is likely
to require the use of encapsulation technologies. The semi-
permeable membranes of these capsules allow diffusion of oxygen
and nutrients into the capsule, and therapeutic agents such as
neurotrophic factors and cellular waste out of the capsule [43–45].
Encapsulation of cells in a biocompatible matrix would protect the
transplanted cells against the immune responses of the host
without the use of toxic immunosuppressant drugs, thereby
minimising the associated risk of transplant rejection [46,47]. In
addition, in the cochlea, encapsulation would also prevent cellular
migration from the site of implantation [48].
A recent study demonstrated greater auditory neuron survival
following the implantation of BDNF-expressing fibroblasts,
encapsulated in agarose, into the deaf guinea pig cochlea [34].
However, as agarose is a biodegradable substance, it is not known
how long such protective effects would last. More stable
encapsulation techniques have been developed using non-
biodegradable, biocompatible alginate, in which choroid plexus
cells were viable for at least six months in the brain of rats [47],
and pancreatic islet cells survived for over nine years following
intraperitoneal implantation in a human patient [46].
The current study investigated cell-based techniques as a
potential clinically applicable means of providing neurotrophic
support and promoting auditory neuron survival in deafness in vivo.
Specifically, we combined cell-based gene transfer with alginate
encapsulation technology to assess the survival effects of
encapsulated BDNF-expressing Schwann cells on auditory neu-
rons in the deaf guinea pig.
Methods
Ethics Statement
All animal experiments were performed in accordance with the
Code of Practice For the Care and Use of Animals For Scientific
Purposes of the National Health and Medical Research Council of
Australia, and the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health, USA. Experiments
were performed under the approval of the Animal Research and
Ethics Committee of the Royal Victorian Eye and Ear Hospital
(Project Number 07/143A), Melbourne, Australia.
Preparation of BDNF-expressing Schwann cells
Schwann cell transfections. Expression plasmids encoding
for the reporter gene enhanced green fluorescent protein (EGFP)
or C-terminal EGFP-tagged rat prepro BDNF were kindly
provided by Dr Volkmar Lessmann, from the Johannes
Gutenberg Universita ¨t, Mainz, Germany. The BDNF expression
vector was constructed by insertion of the complete sequence of rat
prepro BDNF cDNA into the cytomegalovirus-promoter driven
pEGFP-N1 expression vector (Clontech, Cambridge, UK) as
previously described [49–51].
Schwann cells were isolated from early postnatal rat sciatic
nerve and purified as previously described [52]. The Schwann
cells were transfected to over-express either EGFP or EGFP-
tagged BDNF using the lipid-based transfection reagent Lipofec-
tamine 2000, as previously described [38]. Briefly, Schwann cells
were grown on poly-L-lysine (Sigma-Aldrich, Castle Hill, NSW,
Australia) coated 75 cm
2 flasks in Schwann cell media (SCM;
Dulbecco’s modified Eagle’s medium [DMEM; Thermo Electron
Corporation, Noble Park, VIC, Australia] containing 2 mM L-
glutamine [Thermo], 50 U/ml penicillin/streptomycin [Thermo],
10% fetal bovine serum [FBS; Thermo], 0.08% bovine pituitary
extract [Sigma-Aldrich] and 2 mM Forskolin [Sigma-Aldrich]), at
37uC, 10% CO2. On the day prior to transfection, Schwann cells
were sub-cultured into poly-L-lysine coated 6-well plates at a
concentration of 2610
5 cells/well, ensuring cells would be in the
log phase of differentiation on the day of transfection.
The Lipofectamine 2000 (Invitrogen, Melbourne, VIC,
Australia) reagent was prepared as per manufacturer’s guidelines,
with 4 mg DNA used for each well of Schwann cells. Schwann
cells were rinsed with phosphate buffered saline (PBS), and fresh
SCM was added to each well. The DNA/lipid complex was
added to each well of Schwann cells and mixed by gently rocking
the plate. The plates were then incubated at 37uC, 10% CO2
overnight.
The following day, the presence of the EGFP reporter gene
under direct fluorescence microscopy was used to confirm
successful transfection. Schwann cells were sub-cultured and after
a further 24 hours selection of stable transformants commenced
with the addition of geneticin (G418 sulphate, 400 mg/ml;
Invitrogen). Following two weeks of selective pressure the cells
were purified by fluorescence activated cell sorting and the
resultant BDNF-Schwann cells and control EGFP-Schwann cells
were maintained under selective conditions (200 mg/ml geneticin)
and sub-cultured every 3–4 days.
Conditioned media was collected at weekly intervals for up to
four weeks, and the concentration of BDNF secreted by the
BDNF-Schwann cells was determined via enzyme linked im-
munosorbant assay (ELISA) analysis of conditioned media using
an Emax Immunoassay System kit (Promega, Annandale, NSW,
Australia) (n$8).
Encapsulation. The BDNF-Schwann cells were encapsulated
in a biocompatible matrix (Immupel
TM) courtesy of our
collaborative partner, Living Cell Technologies Limited [47].
Briefly, a single cell suspension of BDNF-Schwann cells was
mixed with a 1.7% solution of alginate at a ratio of 1.72610
6 cells/
mL alginate, and this mixture was pumped through a fine aperture
nozzle into a bath of calcium chloride (1.2%). The resulting gelled
beads were washed and serially coated with poly-L-ornithine
(0.1%), poly-L-ornithine (0.05%) and alginate (0.17%), and were
then washed in saline and treated with sodium citrate to chelate
calcium and thus liquefy the intra-capsular alginate. The resultant
capsules were 500–600 mm in diameter, and contained
approximately one thousand BDNF-Schwann cells (Figure 1A).
Empty alginate capsules were prepared in the same way, but
without the cells (Figure 1B).
In vivo procedures
Ototoxin-induced deafening. A total of 23 pigmented
guinea pigs of both sexes (400–600 g) were used for this study.
Animals were anaesthetised with a combination of intramuscular
(i.m.) ketamine (40 mg/kg; Parnell Laboratories, Alexandria,
NSW, Australia) and xylazine (4 mg/kg; Troy Laboratories,
Smithfield, NSW, Australia). All animals had otoscopically
normal tympanic membranes and normal hearing was
confirmed by click-evoked auditory brainstem responses (ABRs)
with thresholds of ,43 decibels peak equivalent sound pressure
level (dB p.e. SPL) [17]. One week later, animals were
anaesthetised using 3–4% isoflurane gas (APS Specialty
Chemicals, Seven Hills, NSW, Australia) delivered in 100%
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1 L/kg/min oxygen for maintenance. Guinea pigs were deafened
via an intravenous infusion of the loop diuretic frusemide
(130 mg/kg; Troy Laboratories) followed by a subcutaneous
(s.c.) injection of the ototoxic aminoglycoside kanamycin
sulphate (520 mg/kg; Sigma-Aldrich).
Implantation surgery. Five days post-deafening, the
animals were anaesthetised with ketamine (60 mg/kg, i.m.) and
xylazine (4 mg/kg, i.m.) and ABRs were performed to confirm
ototoxin-induced deafness. All animals exhibited a severe-
profound SNHL, as indicated by click-evoked ABR thresholds
of .93 dB p.e. SPL in both ears. Animals then underwent
surgery using our standard surgical techniques [8,28]. Briefly,
under aseptic conditions, a postauricular incision was made
behind the left ear to expose the tympanic bulla. A 1 mm cutting
burr was used to open the bulla and enable visualisation of the
basal turn of the cochlea, and a 0.6 mm diamond drill piece was
used to make a cochleostomy, approximately 1 mm in diameter,
in the scala tympani at the level of the basal turn. Alginate
capsules (10–12) containing BDNF-Schwann cells (eBDNF-SC
cohorts) or empty capsules (control cohorts) were slowly injected
into the cochlea via a cannula. The cochleostomy was sealed with
muscle and the wound closed in two layers. The animals survived
for experimental periods of two weeks (2 w) or four weeks (4 w)
post-implantation. The experimental cohorts are summarised in
Table 1.
Histology. Following the experimental period, the animals
were euthanized with an intraperitoneal injection of
pentobarbitone sodium (160 mg/kg; Troy Laboratories) and
intracardially perfused with heparinised normal saline followed
by 10% neutral buffered formalin. The cochleae were harvested
and decalcified in 10% ethylenediamine-triacetic acid in 0.1 M
phosphate buffer. The cochleae were then embedded in OCT
Compound (Tissue-Tek; ProSciTech, Thuringowa, Qld,
Australia) and sectioned on a cryostat at 12 mm. Sections were
stained with haematoxylin and eosin.
Analysis and Statistics
BDNF expression by BDNF-Schwann cells and control (EGFP)
Schwann cells was quantified by ELISA analysis of conditioned
media and expressed as picograms of BDNF per day, per million
cells. Statistical differences in the amount of BDNF produced over
time were identified using a one-way analysis of variance
(ANOVA), and Dunn’s Method was used for multiple compari-
sons. A difference was considered statistically significant at
P,0.05.
Auditory neuron survival was quantified in three representative,
non-consecutive mid-modiolar sections for each experimental
animal using a Zeiss microscope and Axiovision software. The
absolute number of surviving auditory neurons with a clear
nucleus and nucleolus were counted and the cross-sectional area of
Rosenthal’s canal from lower basal to the cochlear apex was
measured. Auditory neuron density (neurons/mm
2) was calculated
for each cochlear region from lower basal to the apex, and the
data is presented as an average across all of these regions. Results
are expressed as mean 6 standard error of the mean (SEM). Due
to the surgical procedures involved, any protection afforded by the
eBDNF-SCs is best controlled for by the empty control cohort.
Therefore, a two-way ANOVA was used to determine the effects
of both treatment (eBDNF-SC versus control) and treatment
duration (2 w versus 4 w), with data considered statistically
significant if P,0.05.
Results
Over-expression of BDNF by Schwann cells
Fluorescence microscopy confirmed that Schwann cells were
successfully transfected to over-express BDNF, with transfected
cells appearing green due to the presence of the EGFP reporter
gene. In addition, successful transfection was confirmed by ELISA
analysis of conditioned media. Immediately post-transfection, the
BDNF-Schwann cells produced a significantly greater amount of
BDNF (568.80664.34 pg/day/10
6 cells [mean 6 SEM]) than
Figure 1. Alginate capsules in vitro. (A) Alginate capsules containing BDNF-Schwann cells and (B) empty control capsules. Capsules are 500–
600 mm in diameter. Scale bar=250 mm.
doi:10.1371/journal.pone.0018733.g001
Table 1. Experimental Cohorts.
Cohort Treatment
Experimental
period
Number of
animals
eBDNF-SC-2 w Encapsulated
BDNF-Schwann cells
2 weeks 5
eBDNF-SC-4 w Encapsulated
BDNF-Schwann cells
4 weeks 6
Control-2 w Empty capsules 2 weeks 6
Control-4 w Empty capsules 4 weeks 6
Summary of experimental cohorts used in the study. Animals received
implantations of either encapsulated BDNF-Schwann cells (eBDNF-SC) or empty
capsules (control), and survived for either two or four weeks post-implantation.
doi:10.1371/journal.pone.0018733.t001
A Cell-Based Therapy for Auditory Neuron Survival
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18733control EGFP-Schwann cells (12.1263.73 pg/day/10
6 cells)
(P,0.001). There was a large and significant (P,0.001) decrease
in BDNF production in the second week post-transfection
(172.89612.85 pg/day/10
6 cells), although this was still signifi-
cantly more BDNF than that produced by the control EGFP-
Schwann cells, and BDNF expression by the BDNF-Schwann cells
remained significantly greater than controls for the four week post-
transfection period (P,0.05; Figure 2).
Implantation of alginate capsules
Ototoxically deafened guinea pigs were divided into four groups
and implanted with alginate capsules containing BDNF-Schwann
cells (eBDNF-SC) or empty capsules (control) for either two weeks
(2 w) or four weeks (4 w). Figure 3 shows histological images of
encapsulated BDNF-Schwann cells implanted into the basal turn
of the cochlea. The capsules were 500–600 mm in diameter and
contained clusters of BDNF-Schwann cells. Histological processing
led to some distortion of the spherical shape of the capsules, as well
as some damage to the capsule wall (Figure 3A, arrow). We also
observed some tissue response in both eBDNF-SC and control
capsule cohorts, which was typically localised to the region of the
cochleostomy. Importantly, there was no fibrous tissue in the more
apical regions of the cochlea. A cluster of encapsulated BDNF-
Schwann cells in situ can be seen at higher magnification in
Figure 3B.
Survival effects of encapsulated BDNF-Schwann cells on
auditory neurons in vivo
Ototoxin exposure led to a complete loss of the sensory
epithelium of the organ of Corti, which was apparent in all
animals of each treatment group. Histological images showing
auditory neuron survival in Rosenthal’s canal of the lower basal
turn of the deaf guinea pig cochlea, for each of the experimental
cohorts, are shown in Figure 4. Enhanced auditory neuron
survival is apparent in both eBDNF-SC cohorts (2 w and 4 w)
compared to the time-matched controls. In addition, the auditory
neurons in the eBDNF-SC treated cochleae displayed morpho-
logical and histological characteristics typical of healthy cells, with
round cell bodies and identifiable nuclei and nucleoli.
Figure 5 illustrates auditory neuron density, averaged across the
cochlea from base to apex, for all experimental cohorts. Auditory
neuron survival in the control-2 w cohort was 770.97627.20
neurons/mm
2 (mean 6 SEM). In comparison, auditory neuron
survival in the eBDNF-SC-2 w cohort was significantly greater
(P,0.05) at 975.376127.02 auditory neurons/mm
2, which is a
26% increase in survival following the implantation of encapsu-
lated BDNF-Schwann cells. A significant (P,0.05) rescue effect
was also observed in the eBDNF-SC-4 w cohort (637.02698.55
neurons/mm
2) in comparison to the control-4 w group
(447.8623.27 neurons/mm
2), which was equivalent to a 42%
increase in auditory neuron survival in the eBDNF-SC treated
cochleae. A two-way ANOVA found there was a main effect of
‘treatment’ (P,0.05), indicating that cell-based BDNF treatment
enhanced auditory neuron survival in comparison to empty
control capsules. There was also a main effect of ‘treatment
duration’ (P,0.001) with a greater proportion of auditory neuron
rescue in the four-week cohort (42%) versus the two-week cohort
(26%), despite the continued auditory neuron degeneration with
the longer period of deafness. There was no interaction between
treatment and treatment duration (P=0.343).
Discussion
The current study is the first to use ex vivo neurotrophin
treatment in conjunction with non-biodegradable cell encapsula-
tion to deliver BDNF into the cochlea and promote auditory
neuron survival in the deaf guinea pig.
These findings demonstrate that cell-based neurotrophin
treatment is a viable option for supporting auditory neuron
survival in deafness. Implantation of eBDNF-SCs resulted in
Figure 2. BDNF expression by BDNF-Schwann cells post-transfection. The amount of BDNF produced by the BDNF-Schwann cells was
quantified by ELISA analysis of conditioned media. BDNF expression was greatest one week after transfection, but after four weeks was still
significantly greater (P,0.05) than that of control Schwann cells expressing EGFP only (indicated by dotted line).
doi:10.1371/journal.pone.0018733.g002
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2 after two weeks,
and 637.02698.55 neurons/mm
2 after four weeks. Previously, we
have reported auditory neuron density in the normal hearing
guinea pig to range between approximately 800–950 neurons/
mm
2 [17,22]. This indicates that auditory survival after two weeks
of cell-based BDNF treatment is similar to that seen in normal
hearing animals. These findings are therefore an important step in
the path to developing a clinically transferable technique for the
delivery of neurotrophins to the deaf cochlea.
It is hypothesised that preventing auditory neuron degeneration
in deafness will improve the benefits to, and outcomes for,
cochlear implant patients. However, the majority of neurotrophin
Figure 3. Alginate capsules in vivo. (A) Histological section showing two alginate capsules containing clusters of BDNF-Schwann cells (asterix), in
the basal region of the deaf guinea pig cochlea. One capsule was damaged during the histological processing, leading to rupture of the capsule wall
(arrow). The large cochleostomy required for insertion of the capsules is outlined, and a vigorous tissue response is apparent in this area. It should be
noted that the tissue response was typically localised to the region of the cochleostomy and there was no fibrous tissue in the more apical regions of
the cochlea. (B) A higher magnification image showing a capsule containing BDNF-Schwann cells within the basal turn of the deaf guinea pig cochlea.
The capsule walls are indicated by arrowheads. ST=scala tympani; SM=scala media; SV=scala vestibuli; RC=Rosenthal’s canal.
doi:10.1371/journal.pone.0018733.g003
Figure 4. Photomicrographs showing auditory neurons in Rosenthal’s canal for each of the experimental cohorts. Histological
sections show Rosenthal’s canal in the lower basal turn of the deaf guinea pig cochlea implanted with either encapsulated BDNF-Schwann cells or
empty control capsules, for either two or four weeks. Auditory neurons were identified and counted based upon the presence of an identifiable cell
soma and a clear nucleus and nucleolus. Examples are indicated by arrow heads. There are more auditory neurons in cochleae implanted with
encapsulated BDNF-Schwann cells than in cochleae receiving empty capsule control implants.
doi:10.1371/journal.pone.0018733.g004
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in human patients [27,53]. For example, intracochlear cannula-
based infusion has a significant risk of infection that is unacceptable
for human cochlear implant recipients. Furthermore, osmotic
pump-based systems have a finite drug reservoir and neurotro-
phin-induced auditory neuron survival is not maintained beyond
the treatment period [8]. In addition, the use of alternative drug
delivery systems [54,55] may be precluded by the long-term
bioactivityofneurotrophinsunderphysiologicalconditions,whichis
currently unknown. The application of neurotrophic factors via
application on and diffusion through the round window membrane,
while appealing due to the non-invasive and atraumatic nature of
the procedure, provides only short-term delivery [56] and may be
compromised by non-uniform distribution through the cochlea
[57,58] as well as variability in membrane permeability due to
cochlear pathologies [59].
Therefore, cell-based delivery of neurotrophins has the potential
to overcome these issues by eliminating the extracochlear elements
that could facilitate the transmission of infection into the cochlea,
while providing continuous production and secretion of neuro-
trophic factors. In addition, cells genetically modified to express
neurotrophins can do so long-term, for $13 months [42], and so
these techniques have the potential to achieve long-term
neurotrophin secretion and long-term or possibly permanent
rescue of auditory neurons from deafness-induced degeneration.
Cell-based neurotrophin treatment meets a number of other
important criteria for clinical application in the cochlea. Firstly,
neurotrophin delivery is more physiologically relevant in terms of
amount and dose rate. The potential side effects of excessive
neurotrophin treatment, as may occur with pump-based systems,
is currently unknown, but may be significant since, in addition to
neuronal survival and differentiation effects, neurotrophins can
also elicit changes in ion channel properties and neurotransmitter
release, and are important in modulating activity-dependent
neuronal plasticity that is essential for the functional and structural
refinement of neuronal circuits [60,61].
Importantly, cell-based BDNF treatment in this study resulted
in similar auditory neuron survival after four weeks to that
described previously using mini-osmotic pump infusion of BDNF
[9], despite the large difference in the amount of neurotrophin
delivered. Therefore, effective auditory neuron survival can be
achieved using cell-based neurotrophin treatment, further sup-
porting such delivery methods as a viable means of providing
neurotrophic support to promote auditory neuron survival in
deafness.
A further consideration for the clinical application of cell-based
therapies in the cochlea is the potential migration or dispersal of
cells from the site of implantation, given the patency of the
cochlear aqueduct with the cerebrospinal fluid of the central
nervous system. The implantation of cells in suspension into the
fluid-filled spaces of the cochlea can result in migration of the cells
throughout the cochlea and into the vestibular organs [48], and
unilateral viral inoculation of the cochlea also led to gene
expression in the contralateral cochlea and CNS [62,63]. The
predisposition of migration or spread from the cochlea due to the
presence of the cochlear aqueduct is therefore an important safety
consideration for implanting cells into the cochlea, which can be
prevented by the use of cell encapsulation.
A further feature of encapsulation technologies is protection
against immunological responses without the use of toxic
immunosuppressant drugs. This is especially important in
xenotransplantation studies, such as the current study where rat
cells were transplanted into the guinea pig. The alginate
encapsulation technique used in this study is reported to be
biocompatible and well tolerated following implantation into
various species, including human, and for up to nine years [46].
These studies also demonstrate that this encapsulation technique is
suitable for long-term survival of the encapsulated cells. While we
did see some tissue response in the current study following surgery
(Figure 3), this was observed in both eBDNF-SC and control
capsule cohorts, and was localised to the region of the
cochleostomy. Previously, in studies using cannula insertion and
Figure 5. The effects of cell-based neurotrophin treatment on auditory neuron survival in the deaf guinea pig. Implantation of
encapsulated BDNF-Schwann cells (eBDNF-SCs) resulted in enhanced auditory neuron survival in comparison to empty capsules, over both two and
four weeks (* P,0.05). The number of surviving auditory neurons was calculated as an average across all cochlear turns.
doi:10.1371/journal.pone.0018733.g005
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a fibrous tissue reactions [8,9]. The tissue response we observed in
the present study is most likely due to the large cochleostomy that
was required for the insertion of the capsules, rather than a
reaction to the capsules themselves. Despite the small size of the
capsules (500–600 mm diameter), they were much larger than the
cannula used in mini-osmotic pump studies (,160 mm diameter),
and as a result the size of the cochleostomy required for capsule
implantation was significantly greater, and may have elicited a
tissue response due to structural damage to the wall of the cochlea.
Furthermore, a muscle plug was used to seal the cochleostomy,
which may have also initiated a fibrous reaction within the fluid-
filled spaces of the cochlea. Regardless of the cause, fibrous tissue
reactions, however mild, are undesirable within the cochlea for a
number of reasons [17]. In cochlear implant patients fibrous tissue
will lead to increased electrode impedance and consequently
increased power consumption, thereby reducing the efficacy of the
device. Neurotrophin diffusion and efficacy may also be impacted
by fibrous tissue reactions. Future studies using encapsulated cell
transplantation may utilise a round window approach for
implantation to minimise such effects.
The size of the capsules may also limit depth of insertion into
the cochlea. The scala tympani of the guinea pig cochlea has a
cross-sectional area of approximately 1300 mm
2 at its widest point
near the base, and narrows to approximately 500 mm
2 within
4 mm from the round window [64]. These dimensions indicate the
insertion of capsules into the guinea pig cochlea will be restricted
to the basal region, consistent with what we observed in this study.
The human scala tympani is much larger than that of the guinea
pig, almost 3000 mm
2 at its widest point basally [65], although
insertion of capsules in the human cochlea would still be restricted
to the base and middle turns.
Despite the localisation of the capsules to the basal cochlear
region near the site of implantation, we did not observe any
localised survival effects (data not shown). This is also consistent
with some of our previous work [8,9], and suggests that the BDNF
was effectively distributed throughout the cochlea. However, a
recent study implanting BDNF-expressing fibroblasts, encapsulat-
ed in agarose, into the cochlea of deaf guinea pigs demonstrated
that auditory neuron survival was greater in the vicinity of the
basal turn, adjacent to the implant site [34]. Similarly, it has been
reported that auditory neuron survival following neurotrophin
treatment and chronic electrical stimulation was greatest in the
basal region, adjacent to the implantation site [17]. These
differences may be a result of the different experimental
techniques used, as compared to the current study. For example,
in the study by Rejali et al. (2007) in which the BDNF-expressing
fibroblasts were seeded onto an electrode array, the effects may
have been limited to the insertion depth into the cochlea, and the
agarose may have reduced the diffusion of BDNF through the
cochlea [34]. Similarly, the increased auditory neuron survival
seen basally following BDNF treatment and chronic electrical
stimulation may reflect the localised current distribution from the
electrode in that model [17].
The present study has utilised encapsulation technologies to
provide cell-based BDNF treatment to the deaf cochlea to support
auditory neuron survival. While this provides proof-of-concept
that such a technique is clinically applicable, further studies are
required that address the issue of long-term auditory neuron
survival in deafness. This will require the use of cells that are
confirmed to secrete the desired neurotrophins for extended
periods of time, and that are implanted for longer than four weeks,
preferably in conjunction with a cochlear implant.
Conclusion
The findings from this study suggest that cell-based neurotro-
phin treatment, incorporating encapsulation technologies, pro-
vides a clinically transferable therapeutic option for the delivery of
neurotrophic factors to reduce or prevent auditory neuron
degeneration in sensorineural hearing loss. Long-term studies
investigating the combined application of cell-based neurotrophin
treatment and chronic electrical stimulation from a cochlear
implant are expected to further enhance auditory neuron survival
in the deaf cochlea, thereby enhancing and extending the benefits
of the cochlear implant.
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